Periadventitial rapamycin-eluting microbeads promote vein graft disease in long-term pig vein-into-artery interposition grafts

Circulation: Cardiovascular Interventions

Volumn 3, Issue 2, 2010, Pages 157-165

  Rajathurai, Thirumaran ^a   Rizvi, S Imran ^a   Lin, Hua ^a   Angelini, Gianni D ^a   Newby, Andrew C ^a   Murphy, Gavin J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Atherosclerosis; Drugs; Microspheres; Muscle; Smooth; Vein bypass

Indexed keywords

MICROSPHERE; POLYVINYL ALCOHOL; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKENING; ARTERY GRAFT; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL WALL; CAROTID ARTERY; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; SAPHENOUS VEIN GRAFT; SMOOTH MUSCLE FIBER; SWINE; VASCULAR SMOOTH MUSCLE; VEIN GRAFT DISEASE;

ANIMALS; CAROTID ARTERIES; CELL PROLIFERATION; CORONARY ARTERY BYPASS; GRAFT OCCLUSION, VASCULAR; HUMANS; MICROSPHERES; MODELS, ANIMAL; MYOCYTES, SMOOTH MUSCLE; NEOVASCULARIZATION, PATHOLOGIC; SAPHENOUS VEIN; SIROLIMUS; SWINE; TRANSPLANTATION, ISOGENEIC; TUNICA INTIMA;

EID: 77953660031     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.109.864660     Document Type: Article

References (27)

1. The Society of Cardiothoracic Surgeons of Great Britain and Ireland National Adult Cardiac Surgical Database Report 2003. Oxfordshire, UK: Dendrite Clinical Systems; 2003.
2. Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, Thottapurathu L, Krasnicka B, Ellis N, Anderson RJ, Henderson W; VA Cooperative Study Group. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol. 2004;44:2149-2156.
3. Sabik JF, Lytle BW, Blackstone EH, Houghtaling PL, Cosgrove DM. Comparison of saphenous vein and internal thoracic artery graft patency by coronary system. Ann Thorac Surg. 2005;79:544-551.
4. Campeau L, Hunninghake DB, Knatterud GL, White CW, Domanski M, Forman SA, Forrester JS, Geller NL, Gobel FL, Herd JA, Hoogwerf BJ, Rosenberg Y. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial Post CABG Trial Investigators. Circulation. 1999;99:3241-3247.
5. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, Namini H, Hamdan AD, Roddy SP, Belkin M, Berceli SA, DeMasi RJ, Samson RH, Berman SS; PREVENT III Investigators. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg. 2006;43:742-751.
6. Angelini GD, Lloyd C, Bush R, Johnson J, Newby AC. An external, oversized, porous polyester stent reduces vein graft neointima formation, cholesterol concentration, and vascular cell adhesion molecule 1 expression in cholesterol-fed pigs. J Thorac Cardiovasc Surg. 2002;124:950-956.
7. Ehsan A, Mann J, Dell'Acqu G, Dzau VJ. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg. 2001;121:714-722.
8. Murphy GJ, Newby AC, Jeremy JY, Baumbach A, Angelini GD. A randomised trial of an external Dacron sheath for the prevention of vein graft disease: the Extent Study. J Thorac Cardiovasc Surg. 2007;134:504-505.
9. PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: A randomized controlled trial. J Am Med Assoc. 2005;294:2446-2454.
10. Murphy GJ, Johnson TW, Chamberlain MH, Rizvi SI, Wyatt M, George SJ, Angelini GD, Karsch KR, Oberhoff M, Newby AC. Short-and long-term effects of cytochalasin D, paclitaxel and rapamycin on wall thickening in experimental porcine vein grafts. Cardiovasc Res. 2007;73:607-617.
11. Institute of Laboratory Animal Research, Commission on Life Sciences, National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academies Press; 1996. (NIH publication 85-23, revised 1996).
12. Angelini GD, Bryan AJ, Williams H M J, Soyombo AA, Williams A, Tovey J, Newby AC. Timecourse of medial and intimal thickening in pig arteriovenous bypass grafts: relationship to endothelial injury and cholesterol accumulation. J Thorac Cardiovasc Surg. 1992;103:1093-1103.
13. Klugherz BD, Llanos G, Lieuallen W, Kopia GA, Papandreou G, Narayan P, Sasseen B, Adelman SJ, Falotico R, Wilensky RL. Twenty-eight day efficacy and pharmacokinetics of the sirolimus-eluting stent. Coron Artery. 2002;13:183-188.
14. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ. Stent-based sirolimus therapy reduces neointimal formation and in-stent restenosis in a porcine coronary model. Circulation. 2001;104:1188-1193.
15. George SJ, Zaltsman AB, Newby AC. Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein. Cardiovasc Res. 1997;33:447-459.
16. George SJ, Baker AH, Angelini GD, Newby AC. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther. 1998;5:1552-1560.
17. George SJ, Izzat MB, Gadsdon P, Johnson JL, Yim AP, Wan S, Newby AC, Angelini GD, Jeremy JY. Macro-porosity is necessary for the reduction of neointimal and medial thickening by external stenting of porcine saphenous vein bypass grafts. Atherosclerosis. 2001;155:329-326.
18. Holt DW, Lee T, Johnston A. Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection. Clin Therap. 2000;22: B38-B48.
19. Higuchi Y, Hirayama A, Shimizu M, Sakakibara T, Kodama K. Postoperative changes in angiographically normal saphenous vein coronary bypass grafts using intravascular ultrasound. Heart Vessels. 2002;17:57-60.
20. Schachner T, Zou Y, Oberhuber A, Tzankov A, Mairinger T, Laufer G, Bonatti JO. Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. Ann Thorac Surg. 2004;77:1580-1585.
21. Kawatsu S, Katsuhiko O, Saiki Y, Tabata Y, Tabayashi K. External application of rapamycin-eluting film at anastomotic sites inhibits neointimal hyperplasia in a canine model. Ann Thorac Surg. 2007;84:560-567.
22. Zhang L, Hagen PO, Kisslo J, Peppel K, Freedman NJ. Neointimal hyperplasia rapidly reaches steady state in a novel murine vein graft model. J Vasc Surg. 2002;36:824-832.
23. Zwolak RM, Kirkman TR, Clowes AW. Atherosclerosis in rabbit vein grafts. Arteriosclerosis. 1989;9:374-379.
24. Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution and deposition. Circ Res. 2000;86:879-884.
25. Hata JA, Petrofski JA, Schroder JN, Williams ML, Timberlake SH, Pippen A, Corwin MT, Solan AK, Jakoi A, Gehrig TR, Kontos CD, Milano CA. Modulation of phosphatidylinositol 3-kinase signaling reduces intimal hyperplasia in aortocoronary saphenous vein grafts. J Thorac Cardiovasc Surg. 2005;129:1405-1413.
26. Wilson GJ, Nakazawa G, Schwartz RS, Huibregtse B, Poff B, Herbst TJ, Baim BS, Virmani R. Comparison of inflammatory response after implantation of sirolimus-and paclitaxel-eluting stents in porcine coronary arteries. Circulation. 2009;120:141-149.
27. Sousa JE, Costa MA, Abizaid A, Feres F, Seixas AC, Tanajura LF, Mattos LA, Falotico R, Jaeger J, Popma JJ, Serruys PW, Sousa AG. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation. 2005;111:2326-2399.